Arcutis Biotherapeutics Stock Today
| ARQT Stock | USD 10.77 0.63 6.21% |
Performance0 of 100
| Odds Of DistressOver 57
|
Arcutis Biotherapeutics is selling for under 10.77 as of the 25th of November 2024; that is 6.21 percent increase since the beginning of the trading day. The stock's last reported lowest price was 10.21. Arcutis Biotherapeutics has over 57 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. Equity ratings for Arcutis Biotherapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of October 2024 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 31st of January 2020 | Category Healthcare | Classification Health Care |
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California. Arcutis Biotherapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 117.05 M outstanding shares of which 27.76 M shares are presently shorted by private and institutional investors with about 16.78 trading days to cover. More on Arcutis Biotherapeutics
Moving against Arcutis Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Arcutis Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Todd MA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsArcutis Biotherapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Arcutis Biotherapeutics' financial leverage. It provides some insight into what part of Arcutis Biotherapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Arcutis Biotherapeutics (ARQT) is traded on NASDAQ Exchange in USA. It is located in 3027 Townsgate Road, Westlake Village, CA, United States, 91361 and employs 296 people. Arcutis Biotherapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.19 B. Arcutis Biotherapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 117.05 M outstanding shares of which 27.76 M shares are presently shorted by private and institutional investors with about 16.78 trading days to cover.
Arcutis Biotherapeutics currently holds about 282.17 M in cash with (247.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.47.
Check Arcutis Biotherapeutics Probability Of Bankruptcy
Ownership AllocationThe majority of Arcutis Biotherapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Arcutis Biotherapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Arcutis Biotherapeutics. Please pay attention to any change in the institutional holdings of Arcutis Biotherapeutics as this could imply that something significant has changed or is about to change at the company.
Check Arcutis Ownership Details
Arcutis Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-09-30 | 2.5 M | |
| Ensign Peak Advisors Inc | 2024-09-30 | 2.4 M | |
| Cormorant Asset Management, Llc | 2024-09-30 | 2.3 M | |
| Pivotal Bioventure Partners Investment Advisor Llc | 2024-06-30 | 2 M | |
| Deutsche Bank Ag | 2024-06-30 | 1.9 M | |
| Stempoint Capital Lp | 2024-09-30 | 1.8 M | |
| D. E. Shaw & Co Lp | 2024-09-30 | 1.7 M | |
| Gw&k Investment Management, Llc | 2024-09-30 | 1.6 M | |
| J. Goldman & Co Lp | 2024-09-30 | 1.5 M | |
| Jennison Associates Llc | 2024-09-30 | 11.7 M | |
| Suvretta Capital Management, Llc | 2024-06-30 | 10 M |
Arcutis Biotherapeutics Historical Income Statement
Arcutis Stock Against Markets
Arcutis Biotherapeutics Corporate Management
| JD Esq | General VP | Profile | |
| Patricia Turney | VP Operations | Profile | |
| Todd Edwards | Senior Officer | Profile | |
| Eric McIntyre | Head Relations | Profile | |
| Ayisha Jeter | Head Access | Profile | |
| David Osborne | Chief Officer | Profile | |
| Bethany Dudek | Chief Officer | Profile |
Already Invested in Arcutis Biotherapeutics?
The danger of trading Arcutis Biotherapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Arcutis Biotherapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Arcutis Biotherapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Arcutis Biotherapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Arcutis Stock Analysis
When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.